Allogene Raises $200.4 Million in Stock Offering to Fuel Pipeline

Event summary

  • Allogene Therapeutics closed an underwritten public offering of 87.5 million shares at $2.00 per share.
  • The offering, including partial exercise of underwriters’ options, raised gross proceeds of $200.4 million.
  • Goldman Sachs, Jefferies, and TD Cowen served as joint bookrunners for the offering.
  • Proceeds are designated for general corporate purposes, including clinical trial, R&D, and administrative expenses.

The big picture

The $200.4 million raise provides Allogene with a crucial runway to continue developing its allogeneic CAR T therapies, a field facing challenges in scalability and manufacturing compared to autologous approaches. This offering underscores the ongoing need for biotech companies to access public markets for funding, particularly as R&D costs escalate. The low offering price ($2.00/share) suggests investor concern about the company’s valuation and execution risk.

What we're watching

Shareholder Dilution
The significant share issuance will dilute existing shareholders, and the market will scrutinize whether Allogene can generate sufficient returns to justify the increased share count.
Clinical Trial Progress
The company's ability to effectively deploy the raised capital into advancing its AlloCAR T pipeline through clinical trials will be a key determinant of future valuation.
Market Sentiment
Continued investor confidence in the broader cell therapy space, and specifically Allogene’s approach to off-the-shelf CAR T, will be crucial for maintaining its market position and accessing future capital.

Related topics

Biotechnology